Of Counsel Kyle Faget was quoted in a BioCentury article, “FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress,” about the FDA’s announcement that it will no longer review emergency use authorization requests for laboratory developed tests to diagnose COVID-19.
The article cites an Aug. 24 blog post by Faget, who wrote that bringing an LDT to market without securing FDA premarket approval or clearance of, or an emergency use authorization (EUA), comes at a steep cost to clinical laboratories. “Public Health and Emergency Preparedness Act (PREP Act) protection is not available to clinical laboratories opting to use LDTs without FDA premarket review or authorization,” she wrote.
People
Related News
17 April 2024
In the News
Steven Barth on Allure of Take-Private Deals – 'Public markets aren’t what they’re cracked up to be'
Foley & Lardner LLP partner Steven Barth offers extensive insight on the growing trend of family-owned consumer and retail businesses aiming to go private in the Axios article, “Family-owned companies see allure in take-private deals.”
16 April 2024
In the News
Claire Marblestone Assesses Increased Scrutiny of CA Health Care Transactions
Foley & Lardner LLP partner Claire Marblestone is quoted in the Law360 article, “Struggling Hospitals Seek Mergers As Regulators Push Back.”
15 April 2024
In the News
Nathaniel Lacktman Joins Double Take by Newton Podcast to Talk Telemedicine
Foley & Lardner LLP Nathaniel Lacktman appeared on Newton Investment Management’s Double Take by Newton podcast episode “Modernizing Medicine” to discuss the health care industry’s digital evolution and the benefits of telemedicine.